Lukas Schwentner
A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany
Baaken D, Schmidberger H, Blettner M, Wiegel T, Bartkowiak D, Renner J, Ghilescu V, Merz T, Mose S, Mayr M, Wöckel A, Janni W, Schwentner L, Bekes I, Schmidt M, Merzenich H, Wollschläger D. A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany. Breast 2022; 65:1-7.
09.06.2022A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany
09.06.2022Breast 2022; 65:1-7
Baaken Dan, Schmidberger Heinz, Blettner Maria, Wiegel Thomas, Bartkowiak Detlef, Renner Jona, Ghilescu Voica, Merz Thomas, Mose Stephan, Mayr Manfred, Wöckel Achim, Janni Wolfgang, Schwentner Lukas, Bekes Inga, Schmidt Marcus, Merzenich Hiltrud, Wollschläger Daniel
Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)
Merzenich H, Wollschläger D, Blettner M, Wiegel T, Bartkowiak D, Woeckel A, Janni W, Schwentner L, Bekes I, Schmidt M, Baaken D, Schmidberger H. Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa). Breast Cancer Res Treat 2021
09.10.2021Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)
09.10.2021Breast Cancer Res Treat 2021
Merzenich Hiltrud, Wollschläger Daniel, Blettner Maria, Wiegel Thomas, Bartkowiak Detlef, Woeckel Achim, Janni Wolfgang, Schwentner Lukas, Bekes Inga, Schmidt Marcus, Baaken Dan, Schmidberger Heinz
BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients
Wischnewsky M, Wöckel A, Kreienberg R, Janni W, Wolters R, Blettner M, Müller-Reiter M, Kiesel M, Bekes I, Salmen J, Davut D, Joukhadar R, De Gregorio A, Diessner J, Schwentner L, Ebner F. BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients. Cancers (Basel) 2021; 13
22.06.2021BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients
22.06.2021Cancers (Basel) 2021; 13
Wischnewsky Manfred, Wöckel Achim, Kreienberg Rolf, Janni Wolfgang, Wolters Regine, Blettner Maria, Müller-Reiter Max, Kiesel Matthias, Bekes Inga, Salmen Jessica, Davut Dayan, Joukhadar Ralf, De Gregorio Amelie, Diessner Joachim Diessner, Schwentner Lukas, Ebner Florian
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial
Cámara R, Singer S, Janni W, Rack B, Widschwendter P, Lato K, Fink V, Deniz M, Friedl T, Schwentner L, Bekes I. Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial. Breast Cancer Res Treat 2019; 175:627-635.
21.03.2019Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial
21.03.2019Breast Cancer Res Treat 2019; 175:627-635
Cámara Rafael J A, Singer Susanne, Janni Wolfgang, Rack Brigitte, Widschwendter Peter, Lato Krisztian, Fink Visnja, Deniz Miriam, Friedl Thomas W P, Schwentner Lukas, Bekes Inga
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Schwentner L, Janni W, Kiechle M, Härtl K, Weissenbacher T, Friedl T, Huober J, Scholz C, Wischnik A, Forstbauer H, Rack B, Eichler M, Singer S, Harbeck N, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
04.04.2016Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
04.04.2016Breast 2016; 27:69-77
Schwentner Lukas, Janni Wolfgang, Kiechle Marion, Härtl Kristin, Weissenbacher Tobias, Friedl Thomas W P, Huober Jens, Scholz Christoph, Wischnik Arthur, Forstbauer Helmut, Rack Brigitte, Eichler Martin, Singer Susanne, Harbeck Nadia, Fink Visnja
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Widschwendter P, Jueckstock J, Neugebauer J, Trapp E, Fasching P, Beckmann M, Schneeweiss A, Schrader I, Rack B, Janni W, Andergassen U, Kost B, Friedl T, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Scholz C. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 2015; 17:129.
18.09.2015The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
18.09.2015Breast Cancer Res 2015; 17:129
Widschwendter Peter, Jueckstock Julia, Neugebauer Julia, Trapp Elisabeth, Fasching Peter A, Beckmann Matthias W, Schneeweiss Andreas, Schrader Ines, Rack Brigitte, Janni Wolfgang, Andergassen Ulrich, Kost Bernd, Friedl Thomas Wp, Schwentner Lukas, DeGregorio Nikolaus, Jaeger Bernadette, Schramm Amelie, Bekes Inga, Deniz Miriam, Lato Krisztian, Weissenbacher Tobias, Scholz Christoph